Coleman, R.E. orcid.org/0000-0002-4275-1043 and Rubens, R.D. (1987) 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. British Journal of Cancer, 56 (4). pp. 465-469. ISSN 0007-0920
Abstract
The effect of a single dose of APD on hypercalcaemia has been studied in advanced breast cancer. Twenty-five patients were rehydrated intravenously for 48 h. Twenty-three remained hypercalcaemic and received 5-15 mg APD as a 2 h infusion. Eighteen patients achieved normocalcaemia, 15 after a dose of less than or equal to 15 mg. One patient died within 24 h from rapidly advancing disease and 4 remained hypercalcaemic. Urinary calcium excretion increased during rehydration as glomerular function improved and tubular reabsorption of calcium fell. After APD, calcium excretion fell to normal in 22/24 patients reflecting inhibition of bone resorption. Hydroxyproline excretion remained high. The effect of a single dose of APD on hypercalcaemia lasted a median of 11 days (range 7-17). Transient fever occurred in 2 patients, but there were no other side effects. The possibility of long-term control of osteolysis using a 2 weekly schedule of APD administration is now being studied.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 1987 The Macmillan Press Ltd. |
Keywords: | Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hydroxyproline; Hypercalcemia; Middle Aged; Osteolysis; Pamidronate; Time Factors |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 15 Feb 2021 13:37 |
Last Modified: | 15 Feb 2021 13:37 |
Status: | Published |
Publisher: | Springer Nature (for Cancer Research UK) |
Refereed: | Yes |
Identification Number: | 10.1038/bjc.1987.225 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:170594 |